Cellectis (CLLS) Divestments (2022 - 2023)
Cellectis' (CLLS) quarterly Divestments came in at -$18000.0 in Q2 2023, up 95.98% year-on-year from -$9184.5 in Q2 2022, and down 118.56% quarter-over-quarter from $97000.0 in Q1 2023.
Cellectis (CLLS) Divestments (2022 - 2023) Analysis & Trends
Cellectis' Divestments history runs 2 years deep, the most recent figure standing at -$18000.0 for Q2 2023.
- On a quarterly basis, Divestments rose 95.98% year-over-year to -$18000.0 in Q2 2023; TTM through Dec 2023 was $79000.0, a 117.71% increase from a year earlier, with the FY2023 full-year figure at $79000.0, up 117.71% from the prior year.
- Divestments slipped to -$18000.0 in Q2 2023 per CLLS's latest filing, from $97000.0 in the prior quarter.
- Across five years, Divestments topped out at $177000.0 in Q3 2022 and bottomed at -$448000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -32.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -18,000.00 |
| Mar 31, 2023 | 97,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Sep 30, 2022 | 177,000.00 |
| Jun 30, 2022 | -448,000.00 |
| Mar 31, 2022 | -296,000.00 |